These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 8682282)

  • 41. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
    Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
    Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
    Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
    Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 49. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
    Meijer-van Gelder ME; Look MP; Bolt-de Vries J; Peters HA; Klijn JG; Foekens JA
    J Clin Oncol; 1999 May; 17(5):1449-57. PubMed ID: 10334530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
    Liebert A; Quietzsch D; Beier L
    Anticancer Res; 1999; 19(4A):2571-6. PubMed ID: 10470197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
    Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
    Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor.
    Göhring UJ; Scharl A; Heckel C; Ahr A; Crombach G
    Arch Gynecol Obstet; 1995; 256(3):139-46. PubMed ID: 7574906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical localization of cathepsin D, proliferating cell nuclear antigen and epidermal growth factor receptor in human breast carcinoma analysed by computer image analyser: correlation with histological grade and metastatic behaviour.
    Okamura K; Kobayashi I; Matsuo K; Kiyoshima T; Yamamoto K; Miyoshi A; Sakai H
    Histopathology; 1997 Dec; 31(6):540-8. PubMed ID: 9447385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.